MX2022011452A - Nuevo derivado de pirimidina y composicion para prevenir o tratar enfermedades neurodegenerativas y cancer, que comprende el mismo. - Google Patents

Nuevo derivado de pirimidina y composicion para prevenir o tratar enfermedades neurodegenerativas y cancer, que comprende el mismo.

Info

Publication number
MX2022011452A
MX2022011452A MX2022011452A MX2022011452A MX2022011452A MX 2022011452 A MX2022011452 A MX 2022011452A MX 2022011452 A MX2022011452 A MX 2022011452A MX 2022011452 A MX2022011452 A MX 2022011452A MX 2022011452 A MX2022011452 A MX 2022011452A
Authority
MX
Mexico
Prior art keywords
cancer
preventing
neurodegenerative diseases
composition
pyrimidine derivative
Prior art date
Application number
MX2022011452A
Other languages
English (en)
Inventor
Jin Sook Song
Ho Chul Shin
Chong Hak Chae
Ge Hyeong Lee
Seong Hwan Kim
Jee Hee Suh
Jee Yeon Seo
Jeong Heon Yu
In Hae Ye
Seong Hyeon Sim
Hee Yeon Kang
Ji Hun Lee
Keon Ha Hwang
Original Assignee
Whan In Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210018223A external-priority patent/KR102342803B1/ko
Application filed by Whan In Pharmaceutical Co Ltd filed Critical Whan In Pharmaceutical Co Ltd
Publication of MX2022011452A publication Critical patent/MX2022011452A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un nuevo derivado de pirimidina y una composición para prevenir o tratar enfermedades neurodegenerativas y cáncer, que comprende el mismo, el derivado de pirimidina que tiene una actividad inhibidora de la proteína LRRK2 y que pasa efectivamente a través de una barrera hematoencefálica (BBB) para usarse efectivamente como una composición farmacéutica para prevenir o tratar enfermedades neurodegenerativas y cáncer.
MX2022011452A 2020-03-23 2021-03-12 Nuevo derivado de pirimidina y composicion para prevenir o tratar enfermedades neurodegenerativas y cancer, que comprende el mismo. MX2022011452A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200035257 2020-03-23
KR1020210018223A KR102342803B1 (ko) 2020-03-23 2021-02-09 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
PCT/KR2021/003120 WO2021194144A1 (ko) 2020-03-23 2021-03-12 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
MX2022011452A true MX2022011452A (es) 2022-10-18

Family

ID=77890540

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011452A MX2022011452A (es) 2020-03-23 2021-03-12 Nuevo derivado de pirimidina y composicion para prevenir o tratar enfermedades neurodegenerativas y cancer, que comprende el mismo.

Country Status (10)

Country Link
US (1) US20230219930A1 (es)
EP (1) EP4129994A4 (es)
JP (1) JP2023524935A (es)
CN (1) CN115413278A (es)
AU (1) AU2021243887A1 (es)
BR (1) BR112022018477A2 (es)
CA (1) CA3172750A1 (es)
CL (1) CL2022002512A1 (es)
MX (1) MX2022011452A (es)
WO (1) WO2021194144A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
JP4316893B2 (ja) * 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｓｒｃおよび他のプロテインキナーゼのインヒビター
WO2003011837A1 (en) * 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
CN101910152B (zh) * 2007-11-16 2014-08-06 因塞特公司 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
KR101208198B1 (ko) 2010-08-27 2012-12-04 인제대학교 산학협력단 Ｌｒｒｋ２ 인산화효소 억제 활성을 갖는 화합물을 유효성분으로 함유하는 파킨슨병 치료 또는 예방용 약학조성물
PT2638031T (pt) 2010-11-10 2018-01-03 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2
US8791130B2 (en) 2011-11-29 2014-07-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
CN103864770B (zh) * 2012-12-10 2019-06-11 江苏先声药业有限公司 作为Hedgehog信号传导的嘧啶胺类和吡啶胺类抑制剂
BR112018075569A2 (pt) 2016-06-16 2019-03-19 Denali Therapeutics Inc. pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
KR20200020622A (ko) * 2018-08-16 2020-02-26 재단법인 대구경북첨단의료산업진흥재단 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
US20230219930A1 (en) 2023-07-13
BR112022018477A2 (pt) 2022-11-01
AU2021243887A1 (en) 2022-11-03
CN115413278A (zh) 2022-11-29
JP2023524935A (ja) 2023-06-14
CL2022002512A1 (es) 2023-03-24
WO2021194144A1 (ko) 2021-09-30
CA3172750A1 (en) 2021-09-30
EP4129994A1 (en) 2023-02-08
EP4129994A4 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
CR20210415A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
UA111272C2 (uk) Конденсовані піримідинові похідні для інгібування тирозинкіназної активності
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MX2011010923A (es) Derivado de pirrolopiridina condensado.
MX2018011788A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
CR20190530A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
NZ788133A (en) Cd73 inhibitors
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2021008667A (es) Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2022004143A (es) Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso.
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
BR112022000505A8 (pt) Compostos de 3,4-(anel fundido em 5)-5-fenil-pirrolidin-2-ona n-substituídos como inibidores de enzima isoqc e/ou qc
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
PH12017501668A1 (en) Bace1 inhibitors
MX2022011452A (es) Nuevo derivado de pirimidina y composicion para prevenir o tratar enfermedades neurodegenerativas y cancer, que comprende el mismo.
MX2023007497A (es) Nuevos derivados de quinazolina como inhibidores de sos1 y uso de los mismos.